Pharmaceuticals Australia

Australia MASH (NASH) Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Australia MASH (NASH) Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Stage, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $22.0 Mn Placeholder estimate
Estimate 2025 $31.6 Mn 1.3% of the global market
Projected 2034 $819.2 Mn 2,496.5% Adds $787.7 Mn over 9 forecast years
CAGR 2025–2034 43.6% Faster than 99% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Australia is 1.3% of the global market.
  • In APAC, the largest is China at $193.6 Mn.
  • Fastest growing: India at 44.6% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$787.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
MASH (NASH) Therapeutics Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $22.0 Mn — —
2025 (base) $31.6 Mn +$9.6 Mn —
2026 (forecast) $45.3 Mn +$13.8 Mn +43.6%
2027 (forecast) $65.1 Mn +$19.8 Mn +106.2%
2028 (forecast) $93.4 Mn +$28.4 Mn +196.1%
2029 (forecast) $134.2 Mn +$40.7 Mn +325.2%
2030 (forecast) $192.7 Mn +$58.5 Mn +510.6%
2031 (forecast) $276.6 Mn +$84.0 Mn +776.9%
2032 (forecast) $397.3 Mn +$120.6 Mn +1,159.2%
2033 (forecast) $570.5 Mn +$173.2 Mn +1,708.2%
2034 (forecast) $819.2 Mn +$248.7 Mn +2,496.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $2.42 Bn
  2. North America $1.10 Bn
  3. US $1.07 Bn
  4. Europe $465.3 Mn
  5. APAC $476.6 Mn
  6. Canada $215.7 Mn
  7. China $193.6 Mn
  8. Japan $156.3 Mn
  9. Latin America $125.7 Mn
  10. Middle East $91.1 Mn
  11. Germany $80.1 Mn
  12. France $75.1 Mn
  13. UK $56.7 Mn
  14. Brazil $56.9 Mn
  15. Italy $55.7 Mn
  16. Ecuador $55.5 Mn
  17. India $52.3 Mn
  18. Spain $46.1 Mn
  19. Mexico $41.3 Mn
  20. Saudi Arabia $40.7 Mn
  21. Africa $33.7 Mn
  22. Australia (this report) $31.6 Mn
  23. Russia $26.5 Mn
  24. New Zealand $21.3 Mn
  25. South Africa $17.5 Mn
  26. UAE $12.5 Mn
  27. Egypt $7.0 Mn
  28. Philippines $4.7 Mn
  29. Malaysia $4.2 Mn
  30. Hong Kong $3.7 Mn
  31. Singapore $3.1 Mn
  32. Thailand $2.8 Mn
  33. Kenya $1.4 Mn

Report snapshot

Australia MASH (NASH) Therapeutics Market Analysis at a glance
Market size, 2025$31.6 Mn placeholder estimate
Forecast, 2034$819.2 Mn placeholder estimate
Growth (CAGR), 2025–203443.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledMASH Drugs
SegmentsDrug class, stage and end user (see all)
Key playersMadrigal Pharmaceuticals, Novo Nordisk A/S, Akero Therapeutics, 89bio, Inventiva and 1 more (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials15 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia MASH (NASH) Therapeutics Market Analysis Executive Summary

MASH therapeutics treat metabolic dysfunction-associated steatohepatitis, a serious fatty liver disease that can lead to cirrhosis and liver failure.

Key segments of the MASH (NASH) Therapeutics market include drug class (THR-beta Agonists, GLP-1 Agonists and FGF21 Analogs) and stage (Fibrosis Stage F2-F3 and Compensated Cirrhosis).

Bar chart: Australia MASH (NASH) Therapeutics market size, 2024–2034, placeholder estimates. $22.0 Mn in 2024, $31.6 Mn in 2025 and $819.2 Mn in 2034, 43.6% CAGR.
Australia MASH (NASH) Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia MASH (NASH) Therapeutics Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the MASH (NASH) Therapeutics market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the MASH (NASH) Therapeutics market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the MASH (NASH) Therapeutics market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for MASH (NASH) Therapeutics Market in Australia

The MASH (NASH) Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for MASH (NASH) Therapeutics Market in Australia

MASH (NASH) Therapeutics in Australia: rules, payment and research

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 15 studies on MASH (NASH) Therapeutics that are recruiting, active or about to start in Australia.⁠[3]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for MASH (NASH) Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in MASH (NASH) Therapeutics right now, from free public sources.

Clinical trials

15 active trials in Australia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Regeneron Pharmaceuticals 7 active trials on ClinicalTrials.gov (opens in a new tab)
  2. GSK PLC 4 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Boehringer Ingelheim GmbH 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Eccogene 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Madrigal Pharmaceuticals 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 16 papers since 2021 (worldwide)

  1. Emerging Molecular Targets in MASH/NASH: Linking Pathogenic Mechanisms to Therapeutic Strategies for Improved Pharmacological Management. Current molecular medicine, 2026
  2. The Effect of Prolyl Isomerase Pin1 on the Development of Metabolic Dysfunction-Associated Steatohepatitis and a New Treatment Strategy. International journal of molecular sciences, 2026
  3. Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis. JHEP reports : innovation in hepatology, 2026
  4. [A novel human 3D steatohepatitis model recapitulating disease progression for evaluating the efficacy and mechanism of action of MASH therapeutics]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2026
  5. Why MASLD Trials Underselect the MENA Region Sites and What Sponsors and Regulators Must Change. Therapeutic innovation & regulatory science, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

MASH (NASH) Therapeutics in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the MASH (NASH) Therapeutics market in Australia?
Placeholder estimate: about $31.6 Mn in 2025, rising to about $819.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the MASH (NASH) Therapeutics market in Australia growing?
Placeholder estimate: about 43.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the MASH (NASH) Therapeutics market report cover?
The report splits the market by drug class (THR-beta Agonists, GLP-1 Agonists, FGF21 Analogs, PPAR Agonists), stage (Fibrosis Stage F2-F3, Compensated Cirrhosis) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the MASH (NASH) Therapeutics market?
Key players include Madrigal Pharmaceuticals, Novo Nordisk A/S, Akero Therapeutics, 89bio, Inventiva and Boston Pharmaceuticals.
What is driving the MASH (NASH) Therapeutics market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the MASH (NASH) Therapeutics market.
Who regulates MASH (NASH) Therapeutics in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on MASH (NASH) Therapeutics are running in Australia?
15 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
How much research is published on MASH (NASH) Therapeutics?
PubMed lists 16 papers on MASH (NASH) Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about MASH (NASH) Therapeutics in Australia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Weight Management Supplements in the GLP-1 Era2.6 billion adults are overweight. GLP-1 medicines are changing weight care, while most supplements lack… Snoring and Sleep Apnoea Devices: Sleeping BetterAn estimated 936 million adults have obstructive sleep apnoea, and most are undiagnosed. CPAP machines, oral… Diabetes Medicines: How Treatment Choices Are ChangingWHO counts 830 million people with diabetes, and 59% of adults with diabetes took no medicine for it in 2022…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Australia

See all
Same topic, other categories

Related on liver health and obesity

See the topic